A Whole-genome Sequencing Analysis of
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
13
08
2018
revised:
06
12
2018
accepted:
22
01
2019
entrez:
14
6
2019
pubmed:
14
6
2019
medline:
14
6
2019
Statut:
epublish
Résumé
Tracking the spread of the We obtained clinical isolates and data from the China Gonococcal Resistance Surveillance Programme (China-GRSP) from 2012 to 2013. We sequenced the genomes of 435 clinical isolates of The most prevalent MLST STs in our gonococcal population were MLST ST7827 (n = 74), followed by ST7365 (n = 58), ST1600 (n = 38), ST7367 (n = 35), and ST7363 (n = 29). MLST ST1901 which was reported as the predominant ST in the US was not found in our population. A total of 2512 strains, including additional 2077 published NG strains, were further included for phylogenetic analysis. It generated two distinct lineages - lineage 1 and lineage 2. Analysis of MLST ST1901 in the database indicate that most of MLST ST1901 isolates in the lineage2.6 were Cfx-DS isolates while all isolates in the lineage 2.1 were sensitive to ceftriaxone (77/110 vs. 0/13; p < 0.001). ST1901/lineage 2.6 is a ceftriaxone resistant clone which cannot distinguished by MLST genotyping. In the isolates from our study, the MICs of ceftriaxone for ST7363/lineage 2.6 isolates ranged from 0.008-0.125 mg/L (mean ± SD; 0.054 ± 0.043 mg/L) while those for ST7363/lineage 2.8 isolates ranged from 0.032-0.250 mg/L (0.134 ± 0.085 mg/L). All ST7363/lineage 2.8 isolates contained To our knowledge, current study is the first WGS-based analysis of gonococcal population at national level in Asia. China harbors the different predominant clones associated with decreased susceptibility to ceftriaxone from those clones circulated in other regions. The findings from the study can be not only used as baseline data for future studies in China but also contributable to our understanding on spread of The Chinese Academy Medical Sciences (CAMS) Initiative for Innovative Medicine.
Sections du résumé
BACKGROUND
BACKGROUND
Tracking the spread of the
METHODS
METHODS
We obtained clinical isolates and data from the China Gonococcal Resistance Surveillance Programme (China-GRSP) from 2012 to 2013. We sequenced the genomes of 435 clinical isolates of
FINDINGS
RESULTS
The most prevalent MLST STs in our gonococcal population were MLST ST7827 (n = 74), followed by ST7365 (n = 58), ST1600 (n = 38), ST7367 (n = 35), and ST7363 (n = 29). MLST ST1901 which was reported as the predominant ST in the US was not found in our population. A total of 2512 strains, including additional 2077 published NG strains, were further included for phylogenetic analysis. It generated two distinct lineages - lineage 1 and lineage 2. Analysis of MLST ST1901 in the database indicate that most of MLST ST1901 isolates in the lineage2.6 were Cfx-DS isolates while all isolates in the lineage 2.1 were sensitive to ceftriaxone (77/110 vs. 0/13; p < 0.001). ST1901/lineage 2.6 is a ceftriaxone resistant clone which cannot distinguished by MLST genotyping. In the isolates from our study, the MICs of ceftriaxone for ST7363/lineage 2.6 isolates ranged from 0.008-0.125 mg/L (mean ± SD; 0.054 ± 0.043 mg/L) while those for ST7363/lineage 2.8 isolates ranged from 0.032-0.250 mg/L (0.134 ± 0.085 mg/L). All ST7363/lineage 2.8 isolates contained
INTERPRETATION
CONCLUSIONS
To our knowledge, current study is the first WGS-based analysis of gonococcal population at national level in Asia. China harbors the different predominant clones associated with decreased susceptibility to ceftriaxone from those clones circulated in other regions. The findings from the study can be not only used as baseline data for future studies in China but also contributable to our understanding on spread of
FUNDING
BACKGROUND
The Chinese Academy Medical Sciences (CAMS) Initiative for Innovative Medicine.
Identifiants
pubmed: 31193648
doi: 10.1016/j.eclinm.2019.01.010
pii: S2589-5370(19)30015-X
pmc: PMC6537553
doi:
Types de publication
Journal Article
Langues
eng
Pagination
47-54Références
Trends Genet. 2001 May;17(5):262-72
pubmed: 11335036
Nat Rev Genet. 2003 Apr;4(4):275-84
pubmed: 12671658
Antimicrob Agents Chemother. 2007 Aug;51(8):2784-92
pubmed: 17517841
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Expert Rev Anti Infect Ther. 2009 Sep;7(7):821-34
pubmed: 19735224
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Sex Transm Infect. 2010 Nov;86(6):454-60
pubmed: 20940159
Antimicrob Agents Chemother. 2011 Jul;55(7):3538-45
pubmed: 21576437
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W347-52
pubmed: 21672955
PLoS One. 2012;7(2):e30619
pubmed: 22312429
J Antimicrob Chemother. 2012 Aug;67(8):1858-60
pubmed: 22566592
Future Microbiol. 2012 Dec;7(12):1401-22
pubmed: 23231489
Antimicrob Agents Chemother. 2013 Nov;57(11):5225-32
pubmed: 23939890
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
Lancet Infect Dis. 2014 Mar;14(3):220-6
pubmed: 24462211
Clin Microbiol Rev. 2014 Jul;27(3):587-613
pubmed: 24982323
J Clin Microbiol. 2015 Jan;53(1):191-200
pubmed: 25378573
Antimicrob Agents Chemother. 2015 May;59(5):2695-9
pubmed: 25712352
J Antimicrob Chemother. 2016 Jan;71(1):92-9
pubmed: 26472770
PLoS One. 2015 Dec 08;10(12):e0143304
pubmed: 26646541
Nucleic Acids Res. 2016 Jul 8;44(W1):W242-5
pubmed: 27095192
N Engl J Med. 2016 Jun 23;374(25):2504-6
pubmed: 27332921
MBio. 2016 Jun 28;7(3):
pubmed: 27353752
Lancet Infect Dis. 2016 Nov;16(11):1295-1303
pubmed: 27427203
J Infect Dis. 2016 Nov 15;214(10):1579-1587
pubmed: 27638945
J Antimicrob Chemother. 2017 Jul 1;72(7):1937-1947
pubmed: 28333355
J Infect Chemother. 2017 Jun;23(6):385-389
pubmed: 28446378
PLoS Med. 2017 Jul 7;14(7):e1002344
pubmed: 28686231
Euro Surveill. 2017 Oct;22(42):null
pubmed: 29067905
Nat Rev Genet. 2018 Jan;19(1):9-20
pubmed: 29129921
Emerg Infect Dis. 2018 Feb;24(2):
pubmed: 29131780
Emerg Infect Dis. 2017 Oct;23(13):
pubmed: 29155673
J Antimicrob Chemother. 2018 Feb 1;73(2):353-364
pubmed: 29182725
PLoS Med. 2018 Feb 6;15(2):e1002499
pubmed: 29408881
BMC Genomics. 2018 Feb 27;19(1):165
pubmed: 29482499
Emerg Infect Dis. 2018 Apr;24(4):
pubmed: 29553335
Lancet Infect Dis. 2018 Jul;18(7):758-768
pubmed: 29776807
Ann N Y Acad Sci. 2019 Jan;1435(1):93-109
pubmed: 29876934
Clin Infect Dis. 2019 Jan 18;68(3):505-510
pubmed: 29985996
Nat Microbiol. 2018 Sep;3(9):1032-1042
pubmed: 30082724